On March 2, Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) reported a loss for the fourth quarter that widened from last year, despite a revenue surge, reflecting higher research and development expenses. Total revenues for the quarter surged to $9.19 million from $6.52 million in the same quarter last year, but missed ten Wall Street analysts’ consensus estimate of $10.36 million. On Wednesday shares of Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) closed at $4.32. Company’s sales growth for last 5 years was 52.70%,
Eisai Co., Ltd. and Merck & Co. Inc (NYSE:MRK), announced a clinical trial collaboration to evaluate the safety, tolerability and efficacy of Merck’s anti-PD-1 therapy, pembrolizumab (marketed in the U.S. under the brand name KEYTRUDA), in combination with Eisai oncology compounds lenvatinib mesylate (a multi-targeting RTK inhibitor marketed in the U.S. under the brand name LENVIMA, “lenvatinib”) and eribulin mesylate (a microtubule dynamics inhibitor marketed in nearly 60 countries including Japan, the U.S., and Europe under the brand name HALAVEN, “eribulin”) in multiple clinical trials. On Wednesday shares of Merck & Co. Inc. (NYSE:MRK) closed at $57.88. Company’s sales growth for last 5 years was 9.00% and EPS growth for next 5 years is recorded as 4.74%.
On February 24, Daegis Inc. (NASDAQ:DAEG) announced financial results for its fiscal 2015 third quarter ended January 31, 2015. Total revenue of $5.7 million, compared to $7.9 million year over year. Revenue reflects a $0.9 million decline related to the completion of an eDiscovery matter with the Company’s largest customer and two large product sales totaling $1.1 million in the prior year. On last trading day Daegis Inc. (NASDAQ:DAEG) advanced 1.61% to close at $0.63. Its volatility for the week is 6.97% while volatility for the month is 6.45%. DAEG’s sales growth for past 5 years was 8.50% and its EPS growth for past 5 years was -18.30%. Daegis Inc. (NASDAQ:DAEG) monthly performance is -9.38%.
AT&T‘s acquisition of satellite-TV provider DirecTV (NASDAQ:DTV) could be delayed as an ongoing federal case about access to sensitive cable industry documents is complicating the review process. DIRECTV (NASDAQ:DTV) has 0.10% insider ownership while its institutional ownership stands at 86.00%. In last trading activity company’s stock closed at $88.28.
Citigroup Inc. (NYSE:C) reached a deal to issue most of its global consumer credit and debit cards on MasterCard Inc.’s network. As part of a 10-year agreement, New York-based Citigroup will start to shift more of its consumer business to MasterCard this year, the companies said in a statement Wednesday. Citigroup Inc. (NYSE:C) in last trading activity decreased -0.11% to close at $53.67. Company weekly performance is 3.03% while its quarterly performance stands at 0.62%. Citigroup Inc. (NYSE:C) is -5.74% away from its 52 week high.